Bridget A. Ross Sells 2,500 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 2,500 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at $274,104. This represents a 46.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $95.15 on Thursday. The business has a fifty day simple moving average of $84.08 and a 200 day simple moving average of $86.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 46.19, a PEG ratio of 2.43 and a beta of 0.79. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. LeMaitre Vascular’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular’s dividend payout ratio is presently 38.83%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 287 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the first quarter worth $26,000. NBC Securities Inc. acquired a new position in LeMaitre Vascular during the first quarter worth $36,000. Geneos Wealth Management Inc. raised its stake in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth $47,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LMAT has been the subject of several research reports. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald increased their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $98.00.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.